Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Alam I et al. | Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. | 1983 | Thromb. Res. | pmid:6407140 |
| Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
| Bush LR and Smith SG | Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. | 1986 | Thromb. Res. | pmid:2948294 |
| Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
| Belch JJ et al. | Whole blood white cell aggregation: a novel technique. | 1987 | Thromb. Res. | pmid:2448894 |
| Ostermann G et al. | Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. | 1983 | Thromb. Res. | pmid:6408754 |
| Tsien WH et al. | Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. | 1982 | Thromb. Res. | pmid:7164038 |
| Karlsson H et al. | Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. | 1998 | Thromb. Res. | pmid:9694244 |
| Davis RB and Johnson MF | Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. | 1986 | Thromb. Res. | pmid:3544327 |
| Nishizawa EE and Della-Coletta AA | The formation of a thrombin-like material (TLM) following stimulation of leukocytes. | 1984 | Thromb. Res. | pmid:6484896 |
| Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
| Stahl GL et al. | Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. | 1989 | Thromb. Res. | pmid:2718150 |
| Sloan IG and Firkin BG | Impaired fibrinolysis in patients with thrombotic or haemostatic defects. | 1989 | Thromb. Res. | pmid:2814943 |
| Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
| Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
| Seth P et al. | Effect of platelet activating factor antagonists in different models of thrombosis. | 1994 | Thromb. Res. | pmid:7900097 |
| Kawamura M et al. | Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. | 1993 | Thromb. Res. | pmid:8332959 |
| Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
| Joseph R et al. | Endothelin-1 and human platelet activity. | 1991 | Thromb. Res. | pmid:2028454 |
| Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
| Ostermann G et al. | Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. | 1986 | Thromb. Res. | pmid:3764811 |
| Ishii H et al. | A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. | 1982 | Thromb. Res. | pmid:6897588 |
| Inoue Y et al. | Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. | 1991 | Tohoku J. Exp. Med. | pmid:2063402 |
| Nishihira J et al. | Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. | 1985 | Tohoku J. Exp. Med. | pmid:3001971 |
| Isobe J and Mizuno A | Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. | 1982 | Tokushima J. Exp. Med. | pmid:7170716 |
| Ezoulin MJ et al. | Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. | 2006 | Toxicol In Vitro | pmid:16472967 |
| Baskin SI et al. | The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice. | 1996 | Toxicol. Appl. Pharmacol. | pmid:8806852 |
| Wright DT et al. | Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8048050 |
| Nomura DK et al. | Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. | 2008 | Toxicol. Appl. Pharmacol. | pmid:18164358 |
| Samet JM and Friedman M | Effect of ozone on platelet activating factor metabolism in phorbol-differentiated HL60 cells. | 1992 | Toxicol. Appl. Pharmacol. | pmid:1440609 |
| Hanslik T et al. | Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8079343 |
| Ramos G et al. | Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. | 2004 | Toxicol. Appl. Pharmacol. | pmid:15020195 |
| Feuerstein G et al. | Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis. | 1987 | Toxicol. Lett. | pmid:3660430 |
| Bailie MB et al. | Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. | 1996 | Toxicol. Lett. | pmid:8614909 |
| Mahgoub AA | Thymoquinone protects against experimental colitis in rats. | 2003 | Toxicol. Lett. | pmid:12749817 |
| Flaherty MM et al. | Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. | 2012 | Toxicol. Sci. | pmid:22025730 |
| Grandoni KM et al. | Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. | 1992 | Toxicology | pmid:1311467 |
| Pearson JM et al. | Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. | 1997 | Toxicology | pmid:9231696 |
| Gambero A et al. | Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2. | 2004 | Toxicon | pmid:15450921 |
| Teixeira CF et al. | Hyperalgesia induced by Bothrops jararaca venom in rats: role of eicosanoids and platelet activating factor (PAF). | 1994 | Toxicon | pmid:8052996 |
| Shiroma N et al. | Haemodynamic and haematologic effects of Acanthaster planci venom in dogs. | 1994 | Toxicon | pmid:7846692 |
| Havt A et al. | The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers. | 2001 | Toxicon | pmid:11600146 |
| Castro-Faria-Neto HC et al. | Pro-inflammatory activity of enterolobin: a haemolytic protein purified from seeds of the Brazilian tree Enterolobium contortisiliquum. | 1991 | Toxicon | pmid:1796477 |
| Yara A et al. | Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect. | 1992 | Toxicon | pmid:1440631 |
| Rees RS et al. | Plasma components are required for platelet activation by the toxin of Loxosceles reclusa. | 1988 | Toxicon | pmid:3245050 |
| Freire-Maia L and de Matos IM | Heparin or a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus serrulatus scorpion venom in the rat. | 1993 | Toxicon | pmid:8266352 |
| Tai H et al. | TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. | 2004 | Toxicon | pmid:15501291 |
| Melo RC et al. | Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. | 2005 | Traffic | pmid:16138901 |
| Guerrant RL et al. | Diarrhea, demography and cell signaling: lessons from microbial toxins. | 1997 | Trans. Am. Clin. Climatol. Assoc. | pmid:9108674 |
| Shukla SD et al. | Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. | 1989 Jul-Aug | Transfusion | pmid:2546298 |
| Hirt SW et al. | Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. | 1992 | Transpl. Int. | pmid:14621825 |
| Torras J et al. | Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. | 1993 | Transpl. Int. | pmid:8347271 |
| Räisänen A et al. | Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. | 1993 | Transpl. Int. | pmid:8216700 |
| Wang KS et al. | Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. | 1992 | Transplant. Proc. | pmid:1496669 |
| Takada Y et al. | Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. | 2000 | Transplant. Proc. | pmid:10715416 |
| Fukuoka T et al. | Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion. | 1993 | Transplant. Proc. | pmid:8470175 |
| Peyman JA et al. | HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. | 1992 | Transplant. Proc. | pmid:1533073 |
| Taniguchi S et al. | Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. | 1994 | Transplant. Proc. | pmid:8171719 |
| Coughlan AF et al. | In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. | 1993 | Transplant. Proc. | pmid:7692651 |
| Hammer C et al. | Xenogeneic rejection mechanisms shown by intravital microscopy. | 1998 | Transplant. Proc. | pmid:9865335 |
| Takada Y et al. | Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. | 1998 | Transplant. Proc. | pmid:9838621 |
| Fukunaga K et al. | Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. | 1998 | Transplant. Proc. | pmid:9838664 |
| Lloberas N et al. | The ether phospholipids trail: blood timing in renal ischemia-reperfusion injury. | 2002 | Transplant. Proc. | pmid:11959179 |
| Castellvi J et al. | Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. | 2002 | Transplant. Proc. | pmid:11959181 |
| Metcalfe SM et al. | Survival of renal allografted dogs after limited therapy with cyclosporine and the PAF antagonist WEB 2170. | 1991 | Transplant. Proc. | pmid:1871852 |
| Pirotzky E et al. | Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. | 1988 | Transplant. Proc. | pmid:3388505 |
| Keskinoglu A et al. | Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. | 1997 Feb-Mar | Transplant. Proc. | pmid:9122948 |
| Otte KE et al. | Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. | 1990 | Transplant. Proc. | pmid:2349668 |
| Moreno P et al. | Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. | 1993 | Transplant. Proc. | pmid:8395105 |
| Kecskemeti V and Balogh I | Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. | 1995 | Transplant. Proc. | pmid:7482928 |
| Yin M et al. | Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7482939 |
| Spiegel HU et al. | Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. | 1995 | Transplant. Proc. | pmid:7482955 |
| Foegh ML | Eicosanoids and platelet activating factor mechanisms in organ rejection. | 1988 | Transplant. Proc. | pmid:3059615 |
| Mahmoud FF et al. | In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. | 2002 | Transplant. Proc. | pmid:12431672 |
| Borobia FG et al. | Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. | 1993 | Transplant. Proc. | pmid:8356661 |
| Toledo-Pereyra LH and Suzuki S | Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. | 1994 | Transplant. Proc. | pmid:8109001 |
| Iwamoto H et al. | Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:11119873 |
| Da Costa M et al. | Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. | 1990 | Transplant. Proc. | pmid:2389490 |
| Bergmann R et al. | Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. | 1990 | Transplant. Proc. | pmid:2389511 |
| Immunomodulation: other approaches. | 1988 | Transplant. Proc. | pmid:3347955 | |
| Renkonen R et al. | Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. | 1991 | Transplant. Proc. | pmid:1846709 |
| O'Hair DP et al. | Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. | 1992 | Transplant. Proc. | pmid:1566490 |
| Pignol B et al. | Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. | 1988 | Transplant. Proc. | pmid:3259039 |
| Miyatake T et al. | Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. | 2000 | Transplant. Proc. | pmid:10936319 |
| First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. | 1986 | Transplant. Proc. | pmid:3765055 | |
| Minor T et al. | Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. | 1995 | Transplant. Proc. | pmid:7879086 |
| Ide S et al. | Donor administration of PAF antagonist (TCV-309) enhances lung preservation. | 1995 | Transplant. Proc. | pmid:7879103 |
| Takada Y et al. | Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. | 1995 | Transplant. Proc. | pmid:7879169 |
| Yin M et al. | Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7879180 |
| Chávez-Cartaya RE et al. | Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes. | 1994 | Transplantation | pmid:8197604 |
| Pi F et al. | Effect of a platelet-activating factor antagonist and desferrioxamine administration on eicosanoid production in rat pancreas transplantation. | 1994 | Transplantation | pmid:8291097 |
| Lanese DM et al. | Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. | 1994 | Transplantation | pmid:7809931 |
| dos Santos OF et al. | Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation. | 1989 | Transplantation | pmid:2705209 |
| Saumweber DM et al. | Hyperacute rejection in an ex vivo model of renal xenografting. Role of the mediator response and its pharmacologic manipulation by the specific platelet-activating factor antagonist WEB 2086BS. | 1994 | Transplantation | pmid:8108870 |
| Camussi G et al. | Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. | 1987 | Transplantation | pmid:3299910 |
| Yin M et al. | The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. | 1996 | Transplantation | pmid:8633367 |
| Nishiyama R et al. | Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. | 1993 | Transplantation | pmid:8516812 |
| Kawahara K et al. | The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. | 1993 | Transplantation | pmid:8516834 |
| Takada Y et al. | Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in porcine orthotopic liver transplantation. | 1995 | Transplantation | pmid:7839408 |
| Suzuki S et al. | The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. | 2000 | Transplantation | pmid:10868624 |